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  Abstract 
    Background.   A crucial factor concerning the utility of Cancer Registries is the data quality with respect to comparability, 
completeness, validity and timeliness. However, the data quality of the registration of premalignant lesions has rarely been 
addressed. High grade vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN) are premalignant 
lesions which may develop into cancer, and are often associated with infection with the human papillomarvirus (HPV). 
The aim was to evaluate the quality of registration of VIN and VaIN at the Cancer Registry of Norway (CRN).   Material 
and methods.   We re-collected all notiﬁ  cations with high grade VIN and VaIN diagnoses during 2002 to 2007 from pathology 
laboratories, and compared these to the data in the CRN database so as to quantitatively measure the completeness, valid-
ity and timeliness of the data.   Results.   Over the period 2002 to 2007 we estimated the completeness of the 1556 VIN and 
297 VaIN notiﬁ  cations to be 95.0% and 92.9%, respectively. The original and reabstracted topography codes showed major 
discrepancies for 12 of 642 (1.9%) VIN and 7 of 128 (5.5%) VaIN notiﬁ  cations. The original and reabstracted morphology 
codes for VIN and VaIN were identical for 724 out of 814 notiﬁ  cations. Sixteen notiﬁ  cations had a major discrepancy. For 
the period 2002 to 2007 the median time elapsed between date of diagnosis and date of registration were 436 and 441 
days for VIN and VaIN cases, respectively.   Discussion.   Based on the present analysis of the comparability, completeness, 
validity and timeliness of premalignant lesions of vulva and vagina, we conclude that the Cancer Registry of Norway is able 
to monitor such premalignant lesions satisfactorily.     
  In recent decades the role of Cancer Registries has 
expanded beyond the generation of descriptive sta-
tistics and may also include planning, monitoring 
and evaluation of cancer control activities, including 
cancer screening and vaccination programmes, and 
the follow-up of the quality of care for cancer patients 
[1]. A crucial factor concerning the utility of the Reg-
istry in such activities is the quality of the data with 
respect to comparability, completeness, validity and 
timeliness [2,3]. 
  In Norway, it has been compulsory to send noti-
ﬁ  cations of malignant and premalignant lesions to the 
Cancer Registry of Norway (CRN) since 1952 [4]. 
Data quality evaluation has been applied to several 
speciﬁ  c cancers, including cancer of the ovary [5], 
prostate [6], central nervous system [7] and pharynx 
[8]. A recent comprehensive evaluation of the data 
quality of solid and non-solid tumours concluded that 
data from CRN yields comparable data that can be 
considered reasonably accurate, timely and close to 
complete [9]. However, the use of such concepts in 
the evaluation of the data quality of registration of 
premalignant lesions has rarely been applied. 
  Norway has recently introduced a nationwide 
vaccination programme against HPV, the main caus-
ative agent for cervical cancer. In several clinical tri-
als, vaccination has reduced the incidence of cervical 
intraepithelial neoplasia [10,11], a precursor to cer-
vical cancer. HPV also causes premalignant lesions 
in the vulva and vagina [12,13]. High grade vulvar 
intraepithelial neoplasia (VIN) and vaginal intraepi-
thelial neoplasia (VaIN) are premalignant lesions 
which may develop into cancer or spontaneously 
regress [14,15]. In Norway, the incidence rate of vul-
var intraepithelial neoplasia increased three-fold 
from 1973  –  1977 to 1988  –  1992 [16]. 
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  The aim of the present study was to assess the 
data quality for the registration of premalignant 
lesions of high grade VIN and VaIN at the CRN. 
Monitoring the incidences of these premalignant 
lesions is important to appropriately evaluate the 
impact of HPV vaccination in the population. We 
re-collected all notiﬁ  cations with high grade VIN and 
VaIN diagnoses during 2002 to 2007 from pathology 
laboratories, and compared these to the data in the 
CRN database so as to quantitatively measure the 
validity and completeness of the data. We also pres-
ent the comparability and timeliness of VIN and 
VaIN registrations at the Registry.   
  Material and methods   
  Source of information 
  The Cancer Registry of Norway (CRN) collects, codes, 
and stores data on patients with malignant and certain 
premalignant diagnoses by combining information 
from different sources; pathology notiﬁ  cations, clinical 
notiﬁ   cations, death certiﬁ   cates, hospital discharge 
diagnoses and radiation therapy data. Coding and clas-
siﬁ  cation of neoplasms at the CRN have been described 
elsewhere [9]. The major sources of information for 
premalignant lesions are pathology notiﬁ  cations from 
hospitals and private pathology laboratories that send 
copies of histology reports routinely to CRN. These 
notiﬁ   cations also have topography and morphology 
codes from the Norwegian version of the Systematised 
Nomenclature of Medicine (SNOMED). At CRN the 
notiﬁ  cations are registered by a trained medical coder 
who assigns topography and morphology codes accord-
ing to the rules and classiﬁ   cation schemes used at 
CRN which are mainly based on the second edition of 
the International Classiﬁ  cation of Diseases for Oncol-
ogy (ICD-O-2). Notiﬁ  cations are scanned and stored 
in the database and accumulated as one record for 
each patient. This is effectuated by using the 11-digit 
personal identiﬁ  cation number (PIN) issued to every 
newborn Norwegian citizen and to people residing in 
Norway.     
  Histological features of high grade  VIN and  VaIN 
  Vulvar intraepithelial neoplasia (VIN) is a disease 
which shows histological features of disordered mat-
uration and nuclear abnormalities, such as loss of 
polarity, pleomorphism, coarse chromatin, irregular 
nuclear membranes and mitotic ﬁ  gures [17]. Warty, 
basaloid and mixed warty-basaloid are histological 
subtypes of HPV-related VIN, and are referred to as 
high grade VIN (also known as usual VIN (classic) 
VIN2-3 or undifferentiated VIN) [18]. In contrast, 
the differentiated VIN type is not associated with 
HPV. The distinction between high grade VIN and 
differentiated VIN is not registered at the CRN. 
Women with HPV-related vulvar disease have an 
increased risk of concurrent or subsequent cervical 
intraepithelial and vaginal intraepithelial neoplasia 
[15]. The histopathological features of VaIN are sim-
ilar to those of VIN and include hyperkeratosis, 
nuclear enlargement and pleomorphism. We use VIN 
as a synonym for high grade VIN and VIN 2/3, as 
recommended by Sideri et al. [19] and we use VaIN 
as a synonym for high grade VaIN and -VaIN 2/3.     
  Quality measurements   
  Comparability.    The comparability of registry data can 
be deﬁ  ned as the extent to which coding and clas-
siﬁ  cation procedures, and the deﬁ  nitions for record-
ing of speciﬁ  c data items adhere to agreed international 
standards [2]. The topics covered here include the 
deﬁ  nition of incidence of premalignant lesions, inci-
dence date of the lesion and deﬁ  nition of multiple 
lesions either at the same site (topography) or at 
other anatomically close locations.     
 Completeness.     The completeness of cancer registry data 
reﬂ  ects the extent to which all diagnosed incident cancer 
cases occurring in the population are included in the reg-
istry database [3]. To obtain a quantitative measurement 
of the degree of completeness, we performed independent 
case ascertainment by re-collecting notiﬁ  cations from the 
pathology laboratories. We contacted all of the 23 Nor-
wegian pathology laboratories and requested them to re-
identify and send to CRN all pathology notiﬁ  cations with 
histologically veriﬁ  ed VIN and VaIN for the period 2002 
to 2007. A predeﬁ  ned list of the Norwegian SNOMED 
codes for VIN and VaIN (Table I) with corresponding 
WHO descriptions of VIN and VaIN, was provided in the 
request. The period 2002 to 2007 was chosen to: 1) al-
low the hospital laboratories to use electronic systems to 
identify premalignant cases of the selected topographies 
and morphologies; and 2) to ensure that the quality of 
data for estimating VIN and VaIN incidences in the pre-
vaccination era would be satisfactory.     
 Validity  (accuracy) .    Validity is the proportion of cases 
in a dataset with a given characteristic which truly 
have the attribute [2]. We identiﬁ  ed all notiﬁ  cations 
routinely sent to the registry as well as those re-
collected following our request. From the latter we 
further selected a random subset of notiﬁ  cations for 
the medical coders to reabstract. During reabstrac-
tion, the medical coders had on-screen information 
of the patient record available, but did not consult 
previously registered codes for the notiﬁ  cation  at 
hand. This method was chosen to mimic the setting 
in which the codes were originally recorded. We then    Quality of VIN and VaIN registrations at CRN     47
compared the data registered at CRN (the original 
codes) with the data reabstracted from notiﬁ  cations 
re-collected from the pathology laboratories (the re-
abstracted codes). The accuracy analysis of morphol-
ogy coding was performed on 814 (69%) randomly 
chosen notiﬁ  cations. 
  A total of 44 VaIN notiﬁ  cations had an original 
code of cervical topography and a reabstracted code 
of vaginal topography. This disparity was caused by 
a change of coding practice in 2009, before reab-
straction, and therefore was not due to an error in 
coding. These notiﬁ  cations were excluded from the 
accuracy analysis of topography coding, leaving 128 
VaIN notiﬁ  cations for analyses. The accuracy analy-
sis of vulvar topography coding was performed on 
642 notiﬁ  cations. 
  All discrepancies between original and reab-
stracted codes for each record were classiﬁ  ed accord-
ing to severity. We deﬁ   ned a major topographic 
discrepancy as any change in coding of sites. For a 
vulvar lesion a minor discrepancy was deﬁ  ned  as 
variation within vulvar topographies, such as labium 
majus, labium minus, unspeciﬁ   ed labium majus/
minus and unspeciﬁ  ed vulva. 
  We further deﬁ  ned a major morphologic discrep-
ancy as any coding change between low grade lesions, 
high grade lesions and carcinoma. Minor morpho-
logic discrepancies were deﬁ  ned as use of different 
codes to describe high grade VIN and VaIN. These 
distinctions are modiﬁ  ed from Havener [20] with the 
intention of emphasising discrepancies which would 
affect incidence trend estimates.     
  Timeliness.     Timeliness is considered here as the time 
from diagnosis to registration at CRN for each notiﬁ  -
cation. The date of diagnosis is the date at which the 
sample was taken. We estimated timeliness based on 
all VIN and VaIN notiﬁ  cations over the registration 
period 2002 to 2007. Data was extracted from the 
CRN database in November 2009.         
  Results   
  Comparability 
  A patient was deﬁ  ned  as  an   “  incident premalignant 
case  ”   upon registration of a new diagnosis of high grade 
VIN (or VaIN) with no history of histologically con-
ﬁ  rmed high grade lesion or cervical cancer at the same 
anatomical site in the past two calendar years. Women 
with a cancer diagnosis within four months subsequent 
to the high grade lesion were excluded, as these were 
considered   “  missed  ”   cases of invasive cancer. 
  The CRN rule for the registration of incidence 
date of malignancies is to register the earliest date 
reported for a conﬁ  rmed malignant diagnosis and the 
incident date for premalignant VIN and VaIN cases 
are similarly deﬁ  ned as the earliest date on notiﬁ  ca-
tions describing an incident premalignant case. 
  The coding of multiple primary tumours mainly 
follows the recommendation given by the Euro-
pean Network of Cancer Registries (ENCR), using 
groups of topography codes considered as single 
sites (C51-vulva and C52-vagina) and that the rec-
ognition of two or more primary cancers is not time 
dependant. The CRN has in the period 1974 
to 2007 taken into account the premalignant/malig-
nant history of the woman when assigning topogra-
phy to premalignant lesions of vulva and vagina. 
The registration of a cancer or premalignant lesion 
in an adjacent site prior to the new diagnosis usu-
ally resulted in the new diagnosis being assigned 
to the adjacent site. However, no clear rules were 
established at that time, leaving it up to the med-
ical coder at CRN to interpret and assign the 
topography code.     
Table I. From the list of morphology codes for vagina and vulvar sites with terminology descriptions provided for the 23 laboratories 
during re-collection of notiﬁ  cations based on Norwegian SNOMED laboratory coding lists.
Codes Terminology/Description
80102 Carcinoma in situ, NOSa (Intraepithelial carcinoma, NOS)




Papillary squamous cell carcinoma, non-invasive
Papillary squamous cell papilloma with atypia




Squamous cell carcinoma in situ, NOS
Severe dysplasia
Squamous intraepithelial neoplasia
80762 Squamous cell carcinoma in situ with questionable stromal invasion (not microinvasion)
80812 Bowen disease
81402 Adenocarcinoma in situ NOS. Severe dysplasia in glandular epithelium, NOS
74000 Dysplasia, NOS
76086 Mild/moderate dysplasia in glandular epithelium
Others Any other code used locally to represent moderate or severe dysplasia, carcinoma in situ or intraepithelial neoplasia, VIN or VaIN.
The ICD-O/WHO code 80772 is not used in the Norwegian laboratory lists.
aNot otherwise speciﬁ  ed.48   E. Enerly et al.   
  Completeness 
  For the period 2002 to 2007 we performed indepen-
dent case ascertainment. The records created from 
routinely registered pathology notiﬁ   cations in the 
CRN database were compared to records created 
from the notiﬁ  cations re-collected from the pathol-
ogy laboratories. A total of 1853 notiﬁ  cations were 
analysed and showed that 78 of 1556 (5.0%) VIN 
and 21 of 297 (7.1%) VaIN notiﬁ  cations were miss-
ing in the Registry, giving estimates of 95.0% and 
92.9% completeness for VIN and VaIN notiﬁ  cations, 
respectively. There was some variations in complete-
ness over the observed period, both for VIN (2002: 
96.3%, 2003: 96.2%, 2004: 96.1%, 2005: 93.4%, 
2006: 97.9%, 2007: 89.8%) and for VaIN (2002: 
94.1%, 2003: 93.6%, 2004: 92.5%, 2005: 92.9%, 
2006: 92.9%, 2007: 91.7%). The completeness was 
lowest in 2007 at both sites. We also observed that 
the missing notiﬁ  cations were quite evenly distrib-
uted among the 23 pathology laboratories, except for 
one laboratory which submitted only 19 of 30 (63%) 
of their notiﬁ  cations (data not shown). 
  We noticed that 573 more notiﬁ  cations (including 
both VIN and VaIN) were found in the registry than 
were received from the laboratories during re-collection 
(Figure 1). Of the 573 notiﬁ  cations, 184 were coded 
to the anatomical site skin by the pathology laborato-
ries before being coded to VIN or VaIN by the medical 
coders at CRN (Supplementary Table I available at 
http://www.informahealthcare.com/doi/abs/10.3109/
0284186X.2011.624545). In addition, 114 of these 
573 notiﬁ   cations had other laboratory SNOMED 
codes than requested in the list of morphology codes 
sent to the laboratories (Table I). For the period 2002 
to 2007 the average number of notiﬁ  cations per female 
was 1.9 for VIN, and 2.1 for VaIN. Twenty-ﬁ  ve women 
had at least one VIN and one VaIN diagnosed.     
  Validity (accuracy) 
  The original and reabstracted topography codes for 
VIN were identical for 593 of 642 notiﬁ  cations 
(92.4%). Minor and major discrepancies between the 
original coding and reabstracted coding was evident 
for 37 (5.8%) and 12 notiﬁ  cations (1.9%), respectively 
(Table II). No particular pattern of misclassiﬁ  cation of 
vulvar topography codes was evident among the 37 
notiﬁ  cations with minor discrepancy between the orig-
inal and reabstracted topography (Supplementary 
Table II available at http://www.informahealthcare
.com/doi/abs/10.3109/0284186X.2011.624545). The 
original and reabstracted topography codes for VaIN 
were identical for 121 of 128 notiﬁ  cations (94.5%) 
while seven notiﬁ  cations (5.5%) had a major discrep-
ancy between the original coding and reabstracted 
coding (Table II). 
  The original and reabstracted morphology codes 
for VIN and VaIN were identical for 724 of 814 
notiﬁ  cations. A minor discrepancy between the orig-
inal coding and reabstracted coding was evident for 
74 notiﬁ   cations (9.1%). A major discrepancy was 
found for 16 notiﬁ  cations (2.0%), of which 11 (1.4%) 
were coded as carcinomas and ﬁ  ve (0.6%) as low 
grade lesions (Supplementary Table III available at 
http://www.informahealthcare.com/doi/abs/10.3109/
0284186X.2011.624545). 
  We observed that 19 premalignant cases were 
registered with a topography code according to 
ICD-7 only and not according to ICD-O-2 in addi-
tion. These were patients with previous diagnoses 
coded according to ICD-7. We did not identify any 
missing morphology data at CRN on the notiﬁ  ca-
tions examined.     
  Timeliness 
  For the 1478 VIN and 276 VaIN notiﬁ  cations regis-
tered at CRN the median time between date of diag-
nosis and date of registration was 436 (range: 
29  –  2345) and 441 (59  –  1119) days for VIN and 
VaIN cases, respectively. In the period 2002 to 2006, 
the time interval decreased from 739 (58  –  2345) to 
267 (29  –  921) days. In 2007 the median time interval 




Lab (N=1043) CRN (N=1478)
VaIN (N=297)
Lab (N=237) CRN (N=276)
Notifications from Labs only 
Notifications both in CRN and from Labs 
Notifications in CRN only
216 21 60
72.7% 20.2% 7.1%
Figure 1. The completeness of the pathology notiﬁ  cations of VIN (Vulvar Intraepithelial Neoplasia) and VaIN (Vaginal Intraepithelial 
Neoplasia) registered at the Cancer Registry of Norway during 2002 to 2007. “Notiﬁ  cations in CRN only” refers to those notiﬁ  cations 
that were not sent from pathology laboratories during the independent case ascertainment.   Quality of VIN and VaIN registrations at CRN     49
  Discussion 
  To our knowledge, this is the ﬁ  rst study to report esti-
mates of completeness for the registration of VIN and 
VaIN at a Cancer Registry. We can therefore only 
compare our estimates to those reported for cancers. 
Larsen et al. [9] estimated the average completeness 
of invasive vulvar and vaginal cancer incidence regis-
tration at CRN to be 99.8% [9]. Our estimates of 
completeness for the period 2002 to 2007 for VIN and 
VaIN were 95.0% and 92.9%, respectively, with some 
variation between years. One reason for the somewhat 
lower completeness of premalignant lesions than of 
cancer may be that some cancers are obtained from 
death certiﬁ  cates. Cancer mentioned on the death cer-
tiﬁ  cate allows CRN to send a reminder to the hospitals 
that have not yet reported a new cancer case [9]. It 
should also be noted that there is some uncertainty in 
the completeness estimates reported here since the 
pathology laboratories during re-collection of notiﬁ  ca-
tions did not manage to identify at least 573 notiﬁ  ca-
tions that were previously registered as VIN or VaIN 
in the CRN database. It is thus possible that they also 
may have failed to submit notiﬁ   cations not already 
registered by the CRN. The highest percentage of noti-
ﬁ   cations missing in the CRN database occurred in 
2007. This may indicate that a small proportion of the 
2007 notiﬁ  cations were not yet registered in the data-
base at CRN at the time of data extraction. This is in 
line with the observation that timeliness for VIN and 
VaIN was 267 days in 2006, compared to 445 days in 
2007. The registration of a subset of VIN and VaIN 
notiﬁ  cations from 2007 was put on hold due to inter-
nal priorities at CRN and may explain some of the 
increase. The time interval from diagnosis to the noti-
ﬁ  cations is sent to CRN by the pathology laboratories 
could be another source of variation in timeliness. 
  A total of 184 lesions that were assigned skin 
SNOMED topography codes by the pathology labo-
ratories were coded to vulva topography by the med-
ical coders at the CRN. This highlights the importance 
of a national cancer registry that can harmonise the 
coding practices of local pathology laboratories. 
Moreover, it illustrates how discrepancies in coding 
practices may inﬂ   uence completeness estimates in 
quality assessments of disease registration. 
  A VIN or VaIN lesion in a patient with a prior 
premalignant or malignant lesion in a nearby site has 
generally been assigned to the topography of the pri-
mary registration by the CRN medical coders. This 
has led to fewer registrations of VaIN in particular. 
A reason is that far more lesions occur in the cervix 
[21] and it is therefore more likely that a VaIN lesion 
has been assigned to the cervix than a cervical lesion 
has been assigned to the vagina. We have changed the 
coding practice at CRN so that VaIN and VIN cases 
are assigned topography codes according to the site 
of the lesion, regardless of disease history at other 
anatomical locations. The change took effect in 2009, 
and we will also recode retrospectively for the years 
2002 to 2008. We believe that this change of practice 
will give us more reliable data to monitor the results 
of HPV vaccinations on the incidence of HPV-related 
diseases of the vulva and vagina. This change of cod-
ing practice affected 44 notiﬁ   cations with lesions 
originally assigned cervical topography code, but 
during the reabstraction assigned vaginal topography 
code. These were not included in the estimation of 
the accuracy of topography codes assigned to notiﬁ  -
cations at CRN and reabstracted notiﬁ  cations. 
  We have modiﬁ  ed the published deﬁ  nitions of the 
severity of misclassiﬁ  cation of cancers to evaluate the 
accuracy in registration of premalignant lesions. In 
brief, a major discrepancy as opposed to a minor dis-
crepancy affects the incidence rates of VIN and VaIN. 
We could not compare the accuracy of the CRN cod-
ing of VIN and VaIN to other cancer registries since 
no such data, to our knowledge, has been published. 
  We found that 9.1% of the notiﬁ  cations had a 
minor discrepancy between the original and reab-
stracted morphology codes. Minor discrepancies 
occurred even though rules for giving priority to 
some codes over others exist for diagnoses with more 
than one appropriate morphology code. The majority 
of minor discrepancies occurred on notiﬁ  cations 
describing VIN 3/VaIN 3, carcinoma in situ and 
severe atypia/dysplasia in squamous epithelial cells 
for which there are separate morphology codes. The 
number of minor discrepancies should be reduced to 
a minimum by changing the coding practice. This 
entails using fewer morphology codes. 
  The fact that 1.5% VIN and 2.2% VaIN of all 
notiﬁ  cations had a major discrepancy between the 
Table II. Accuracy of topography and morphology codes assigned 
to notiﬁ   cations at Cancer Registry of Norway (CRN) and 
reabstracted notiﬁ  cations.






Na N%N % N %
Topographyb
Vulva 642 593 92.4 12 1.9 37 5.8
Vagina 128 121 94.5  7 5.5  0 0
Total 770 714 92.7 19 2.5 37 4.8
Morphology
Vulva 642 582 90.7 14 2.2 46 7.2
Vagina 172 142 82.6  2 1.2 28 16.3
Total 814 724 88.9 16 2.0 74  9.1
anumber of notiﬁ  cations. 
bDiscrepancies are assigned to vulva or vagina according to the 
topographic code on the reabstracted notiﬁ  cation.50   E. Enerly et al.   
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Natural history of vaginal intraepithelial neoplasia. Cancer 
1991;1:195  –  7.   
    van de Nieuwenhof HP, van der Avoort IA, de Hullu JA.  [15] 
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neoplasia is associated with transcriptionally active human 
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Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 
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    Havener L. Standards for cancer registries volume III:  [20] 
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  Å  rsrapport; 2008.   
original and reabstracted morphology and topography 
codes, indicate that major misclassiﬁ  cation is not a 
signiﬁ  cant problem in the registration of high grade 
VIN and VaIN. 
  The selection of morphology codes used in this 
evaluation of data quality was chosen to assess the fea-
sibility of the CRN to effectively monitor how HPV 
vaccination programmes will impact on the incidence 
of HPV-related premalignant diseases of the vulva and 
vagina. The present analysis indicates that the compa-
rability, completeness, validity and timeliness of high 
grade VIN and VaIN registration is satisfactory, and 
therefore that the Cancer Registry of Norway is able 
to monitor high grade vulvar intraepithelial and vaginal 
intraepithelial neoplasias with adequate precision.   
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